Blog
IS Pharma : Variquel® approval and management continues to shine
Posted 23/11/09
IS Pharma (LSE: ISPH), the international speciality pharmaceutical company, and a real star EIS qualifying issue from 2007 continues to deliver.
Today the group announced that marketing authorizations (‘MAs’) for Variquel,a key product for the group, have now been received for all of the major European markets.
IS Pharma acquired Variquel in April 2008 when it was marketed only in Germany, Austria and Switzerland. They have since successfully completed the European Mutual Recognition Procedure and subsequently obtained the abovementioned MAs, which has enabled IS Pharma to launch Variquel in the UK, France, Ireland, Denmark, Netherlands, Portugal, Sweden and Finland.
Variquel is a rapid-acting vasoconstrictor used in the treatment of oesophageal varices the global market for which is estimated at between £50m - £70m.
The former house broker Noble estimates that Verquel will account for 50% of their estimated revenue growth over financial years 2009 to 2013 and account for 40% of their valuation. Next up is approval in the US!
Management has really done a great job at ISPH!
This entry was posted 9 months, 2 weeks ago and was filed under IS Pharma.
